Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Price Target from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have received an average rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average […]
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) have received an average rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average […]
